Table 1.
Clinical and genomic features of patients whose tumors dedifferentiated after BRAF inhibitor targeted therapy. Genes listed represented mutated genes unless otherwise noted. PTC: Papillary Thyroid Cancer; PDTC: Poorly Differentiated Thyroid Cancer; ATC: Anaplastic Thyroid Cancer
| ID | Age1 | Gender | Timing2 | Intervening systemic therapies3 | Radiation3 | Initial Pathology | Final Pathology | Potential Mechanisms of Resistance |
|---|---|---|---|---|---|---|---|---|
| MSK-THY1 | 66 | F | After / +4 months | Pazopanib | No | PTC | ATC | PIK3CA |
| MSK-THY2 | 70 | F | During / +5 months | None | No | PTC | PDTC | NF2, MET amplification |
| MSK-THY3 | 68 | M | After / +31 months | Lenvatinib | Yes | PTC | ATC | NF2 |
| MSK-THY4 | 68 | M | After / +34 months | None | No | PTC | ATC | None |
| MSK-THY5 | 68 | F | During / +40 months | None | No | PTC | PDTC | NRAS |
| MSK-THY6 | 52 | M | After / +7 months | None | No | PDTC | ATC | ARID2, JAK1, PBRM1 |
| MSK-THY7 | 66 | M | After / +3 months | None | Yes | PDTC | ATC | RASA1, MTOR |
1
Age at first dose of BRAF inhibitor
2
When sequencing was performed relative to course of BRAF inhibition; duration from BRAF inhibitor start date reported for those sequenced during BRAF inhibition, and duration from BRAF inhibitor stop date for those sequenced after BRAF inhibition.
3
Therapies administered between BRAF inhibition and subsequent treatment sequencing